Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats

• Published in: Cancer chemotherapy and pharmacology 1989-01, Vol.23 (5), p.269-275
• Main Authors: MOHAMED DARDIR, HERMAN, E. H, FERRANS, V. J
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Blood Pressure - drug effects; Body Weight - drug effects; Drug Evaluation, Preclinical; Drug Interactions; Drug toxicity and drugs side effects treatment; Epirubicin - toxicity; Heart - drug effects; Kidney - drug effects; Kidney - pathology; Male; Medical sciences; Microscopy, Electron; Miscellaneous (drug allergy, mutagens, teratogens...); Myocardium - pathology; Pharmacology. Drug treatments; Piperazines - therapeutic use; Rats; Rats, Inbred SHR; Razoxane - therapeutic use; Stereoisomerism
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/BF00292402

A study was made of the protective effect of ICRF-187 against the cardiotoxicity and nephrotoxicity produced by epirubicin in spontaneously hypertensive rats (SHR). A total of 20 SHR were divided into 4 groups of 5 animals; the first group received i.v. injections of 1.5 mg/kg epirubicin; the second was treated with i.p. injections of 50 mg/kg ICRF-187 30 min before receiving 1.5 mg/kg epirubicin; the two remaining groups received ICRF-187 and saline, respectively, and served as controls. The experiment was terminated after 12 weekly injections (total cumulative dose of epirubicin, 18 mg/kg). Morphologic studies showed that severe cardiomyopathy manifested by myofibrillar loss and dilatation of the sarcoplasmic reticulum and nephropathy characterized by tubular dilatation and atrophy, protein casts in the lumina of renal tubules, and glomerular vacuolization occurred in SHR given epirubicin alone. Animals receiving the combination of ICRF-187 and epirubicin showed a marked reduction in the severity of cardiomyopathy and a moderate reduction in nephropathy. These changes, and their modification by ICRF-187, were similar to those we have previously observed in SHR treated with total cumulative doses of 12 mg/kg doxorubicin. Such pathologic changes were absent in animals receiving ICRF-187 or saline alone. The findings of this study suggest that ICRF-187 can be used clinically to prevent the cardiotoxicity of epirubicin, particularly in situations in which this drug may have to be given either in large doses or to patients at high risk of developing anthracycline cardiotoxicity.